<h3>享受 TipRanks Premium 50% 折扣，自信投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>CSL（ (AU:CSL) ）的公告現已發佈。</p>
<p>CSL Limited 宣佈了其持續股票回購計劃的最新進展，透露在前一天之前共回購了 2,773,525 股普通全額支付證券，並在前一天額外回購了 46,950 股證券。此次回購舉措是 CSL 有效管理其資本結構的戰略的一部分，可能會提升股東價值並鞏固其市場地位。</p>
<p>（AU:CSL）股票的最新分析師評級為買入，目標價格為 256.00 澳元。要查看 CSL 股票的完整分析師預測列表，請訪問 AU:CSL 股票預測頁面。</p>
<p><strong>關於 CSL 的更多信息</strong></p>
<p>CSL Limited 在生物技術行業運營，專注於創新生物治療和流感疫苗的開發與交付。該公司是血漿衍生療法的全球領導者，在全球多個市場運營，為罕見和嚴重疾病的患者提供必需藥物。</p>
<p><strong>年初至今價格表現：</strong> -33.39%</p>
<p><strong>平均交易量：</strong> 1,150,052</p>
<p><strong>技術情緒信號：</strong> 賣出</p>
<p><strong>當前市值：</strong> 892.3 億澳元</p>
<p>在 TipRanks 的股票分析頁面瞭解更多關於 CSL 股票的信息。</p>

<p>CSL Limited 宣佈了其股票回購計劃的最新進展，回購了 2,773,525 股普通證券，最近又回購了 46,950 股。該舉措旨在管理資本結構並提升股東價值。CSL 主要從事生物技術，專注於生物療法和疫苗。儘管年初至今股價表現為 -33.39%，該股票仍被給予買入評級，目標價為 256.00 澳元</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，自信投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>An announcement from CSL ( (AU:CSL) ) is now available.</p>
<div class="lb-trans"><p>CSL（ (AU:CSL) ）的公告現已發佈。</p>
</div><p>CSL Limited has announced an update on its ongoing share buy-back program, revealing that a total of 2,773,525 ordinary fully paid securities have been repurchased before the previous day, with an additional 46,950 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and reinforcing its market position.</p>
<div class="lb-trans"><p>CSL Limited 宣佈了其持續股票回購計劃的最新進展，透露在前一天之前共回購了 2,773,525 股普通全額支付證券，並在前一天額外回購了 46,950 股證券。此次回購舉措是 CSL 有效管理其資本結構的戰略的一部分，可能會提升股東價值並鞏固其市場地位。</p>
</div><p>The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.</p>
<div class="lb-trans"><p>（AU:CSL）股票的最新分析師評級為買入，目標價格為 256.00 澳元。要查看 CSL 股票的完整分析師預測列表，請訪問 AU:CSL 股票預測頁面。</p>
</div><p><strong>More about CSL</strong></p>
<div class="lb-trans"><p><strong>關於 CSL 的更多信息</strong></p>
</div><p>CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative biotherapies and influenza vaccines. The company is a global leader in plasma-derived therapies and operates in various markets worldwide, providing essential medicines to patients with rare and serious conditions.</p>
<div class="lb-trans"><p>CSL Limited 在生物技術行業運營，專注於創新生物治療和流感疫苗的開發與交付。該公司是血漿衍生療法的全球領導者，在全球多個市場運營，為罕見和嚴重疾病的患者提供必需藥物。</p>
</div><p><strong>YTD Price Performance:</strong> -33.39%</p>
<div class="lb-trans"><p><strong>年初至今價格表現：</strong> -33.39%</p>
</div><p><strong>Average Trading Volume:</strong> 1,150,052</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,150,052</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技術情緒信號：</strong> 賣出</p>
</div><p><strong>Current Market Cap:</strong> A$89.23B</p>
<div class="lb-trans"><p><strong>當前市值：</strong> 892.3 億澳元</p>
</div><p>Learn more about CSL stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析頁面瞭解更多關於 CSL 股票的信息。</p>
</div>

CSL 有限公司更新股票回購進展